Search

Displaying results 1 - 10 of 78 in total
  1. Indication

    Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma

    go.drugbank.com/conditions/DBCOND0147956
    Drugs: Pembrolizumab
  2. Indication

    Advanced, unresectable Malignant Pleural Mesothelioma (MPM)

    go.drugbank.com/conditions/DBCOND0168860
    Drugs: Pembrolizumab
  3. Indication

    High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG

    go.drugbank.com/conditions/DBCOND0144300
    Drugs: Pembrolizumab
  4. Indication

    Metastatic Malignant Pleural Mesothelioma (MPM)

    go.drugbank.com/conditions/DBCOND0168861
    Drugs: Pembrolizumab
  5. Indication

    Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors

    go.drugbank.com/conditions/DBCOND0144301
    Drugs: Pembrolizumab
  6. Indication

    Resectable, locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    go.drugbank.com/conditions/DBCOND0173428
    Drugs: Pembrolizumab
  7. Indication

    Stage 3 Non-Small Cell Lung Carcinoma (NSCLC)

    go.drugbank.com/conditions/DBCOND0144292
    Drugs: Pembrolizumab
  8. Indication

    Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors

    go.drugbank.com/conditions/DBCOND0144302
    Drugs: Pembrolizumab
  9. Indication

    Unresectable Mismatch repair deficient (dMMR) solid tumors

    go.drugbank.com/conditions/DBCOND0144305
    Drugs: Pembrolizumab
  10. Indication

    Metastatic Esophageal Carcinoma

    go.drugbank.com/conditions/DBCOND0120548
    Drugs: Pembrolizumab